BPMC News and Press, Blueprint Medicines Corporation From 07/24/20

An outperformer over the past year, Swiss drug giant Roche ( OTCQX:RHHBY ) has given some of that back lately, with the shares underperforming the broader peer group over the last three months. Second quarter results aren’t going to help that, as the Covid-19 pandemic had a bigger tha...

CAMBRIDGE, Mass. , July 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency's Committee for Medicinal Pr...

CAMBRIDGE, Mass. , July 23, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a...

Blueprint Medicines (NASDAQ: BPMC) announced Tuesday that global biopharma giant Roche Holdings (OTC: RHHBY)  is paying up to $1.7 billion in upfront cash and potential milestones, plus royalties, to obtain commercial rights to market pralsetinib outside the U.S., excluding Greater C...

Building on their 2016 partnershi p aimed at developing up to five kinase inhibitors in cancer, Roche ( OTCQX:RHHBY ) and Blueprint Medicines (NASDAQ: BPMC ) ink a new license and collaboration agreement to develop and commercialize RET inhibitor pralsetinib. More news on: Roche Hol...

CAMBRIDGE, Mass. , July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has entered into a global collaboration with Roche and ...

Blueprint Medicines (NASDAQ: BPMC ) has submitted a marketing application to the FDA seeking approval of RET inhibitor pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. More news on: Blueprin...

CAMBRIDGE, Mass. , July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a New Drug Application (NDA) to the U.S. Food ...

CAMBRIDGE, Mass. , June 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that The Lancet Oncology published data from the NAVIGATOR cl...

Burning Rock Biotech (NASDAQ: BNR ) announces a strategic partnership with CStone Pharmaceuticals ( OTCPK:CSPHF ) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines (NASDAQ: BPMC...